Monkeypox treatment sales will grow through 2036, led by therapeutic treatments at 68.4% of the treatment type segment in 2026. The market is projected to grow from USD 125.5 million in 2026 to USD 325.4 million by 2036, creating an incremental opportunity of USD 199.96 million between 2026 and 2036.